Halozyme sees FY23 adjusted EPS $2.50-$2.65, consensus $2.90

Sees FY23 revenue $815M-$845M, consensus $892.47M. Sees FY23: EBITDA $415M-$440M, royalty revenue $445M-$455M. "In 2022, we project we achieved record revenue of greater than $655 million and we completed the acquisition of Antares Pharma, opening up an expanded set of opportunities for our subcutaneous drug delivery business," said Dr. Helen Torley, president and CEO. "In 2023, we project record revenue of $815 to $845M and greater than 30% growth in EBITDA to $415 to $440 million. As our ENHANZE pipeline advances, we are excited about the future royalty revenue opportunities represented in 2023 by the potential for two new commercial launches, SC efgartigimod and SC atezolizumab."